Kimmelman, Jonathan
Hyun, Insoo
Benvenisty, Nissim
Caulfield, Timothy
Heslop, Helen E.
Murry, Charles E.
Sipp, Douglas
Studer, Lorenz
Sugarman, Jeremy
Daley, George Q.
Article History
First Online: 12 May 2016
Competing interests
: H.E.H. reports grants from Celgene, other from Viracyte, other from Cell Medica, outside the submitted work.
: C.E.M. is a scientific founder and equity holder in BEAT Biotherapeutics, and has a patent enhancing cardiomyocyte survival pending (US 20070166288).
: L.S. reports personal fees from Neurona Therapeutics Inc., outside the submitted work. In addition, L.S. has a patent US 8642334 licensed to CDI, Fujifilm, and a patent US 20150010514 licensed to CDI, Fujifilm.
: J.S. reports personal fees and non-financial support from Merck KGaA, personal fees and non-financial support from Quintiles, personal fees from Novartis, outside the submitted work.
: G.Q.D. reports MPM Capital: Venture Capital Firm, Advisory Committee Member; Paid Consultant. Epizyme, Publicly traded company developing drugs for cancer; Equity Ownership. True North Therapeutics, Inc: Company developing antibodies against complement cascade; Equity Ownership. Solasia: Company licensing compounds developed in USA and Europe for development in Asia; Equity Ownership, Advisory Committee Member Verastem, Inc: Publicly traded company developing drugs for cancer; Stock. Raze Therapeuics: Private start-up company developing drugs for cancer; Options, Advisory Committee Member. Octa: Company developing regenerative medicine treatments for blindness, recently acquired by Astellas Pharma; Paid Consultancy. 28-7: Start-up in seed round of financing seeking to develop anti-cancer drugs by targeting the Lin28/ let-7 axis; Equity and Paid Consultancy.